Diabetic Foot Ulcer Clinical Trial
Official title:
Treatment of Diabetic Foot Ulcers With Inforatio Technique to Promote Wound Healing: a Feasibility Trial
Verified date | October 2019 |
Source | Zealand University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial will examine the feasibility of conducting a definitive randomized clinical trial
that tests whether inforatio technique will reduce time to healing of diabetic foot ulcers.
Inforatio technique is a procedure where small punch biopsies are taken from the wound bed
near the edge of the wound. With this technique, the investigators wish to initiate an acute
inflammatory response that increases the generation of granulation tissue with subsequent
healing by scar formation. Thus, the investigators hypothesize that inforatio technique will
promote healing of diabetic foot ulcers.
Based on clinical experience, the investigators have previously detected a reduction in time
to healing as an unexpected effect when multiple punch biopsies are taken from the wound bed
of diabetic foot ulcers. To the knowledge of the investigators, methods similar to the
inforatio technique has not previously been studied.
Status | Completed |
Enrollment | 12 |
Est. completion date | September 26, 2019 |
Est. primary completion date | September 26, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
INCLUSION CRITERIA: We include diabetic patients with foot ulcers that are more than six weeks old and which are located distal to the malleoli. The diameters of the ulcers must be at least four mms. One wound from each foot of a patient can be included. If a patient's foot have more than one ulcer that meets the abovementioned criteria, the biggest wound is included. If there is no difference in size, the wound that has the most recent onset is included. If two wounds are close to each other and separated by less than 5 mm intact skin, we will consider it as one wound. Wound onset estimates will be patient-reported. EXCLUSION CRITERIA: We exclude following patients: - Patients with dementia and other patients who are not able to give their informed consent. - Patients with gangrene, necrosis deeper than 1mm, osteomyelitis and clinical signs of infection in their foot. Infection is identified by clinical assessment based on the classical signs comprising oedema, pain, warmth, redness and purulent exudates and is assessed by an experienced orthopedic surgeon. - Patients with ulcers that have positive probe-to-bone test and visible joint and tendons - Patients with systolic toe pressure of < 20 mmHg - Patients that, since the onset of their present foot ulcer, underwent vascular surgery in the lower extremity with the same laterality as the foot ulcer. - Patients that, since the onset of their present foot ulcer, underwent surgical off-loading and amputations - Patients that, since the onset of their present foot ulcer, underwent surgical wound revisions in an operating room. - Patients that have an acute phase of Charcot arthropathy in the foot that presents with a foot ulcer. - Patients that take systemic immunosuppressive drugs. - Patients with cancer - Patients with scleroderma |
Country | Name | City | State |
---|---|---|---|
Denmark | Herlev University Hospital, Department of Orthopaedic Surgery | Herlev | |
Denmark | Zealand University Hospital, Department of Orthopaedic Surgery | Køge |
Lead Sponsor | Collaborator |
---|---|
Zealand University Hospital |
Denmark,
Andrews KL, Houdek MT, Kiemele LJ. Wound management of chronic diabetic foot ulcers: from the basics to regenerative medicine. Prosthet Orthot Int. 2015 Feb;39(1):29-39. doi: 10.1177/0309364614534296. Review. — View Citation
Braun L, Kim PJ, Margolis D, Peters EJ, Lavery LA; Wound Healing Society. What's new in the literature: an update of new research since the original WHS diabetic foot ulcer guidelines in 2006. Wound Repair Regen. 2014 Sep-Oct;22(5):594-604. doi: 10.1111/wrr.12220. Review. — View Citation
Braun LR, Fisk WA, Lev-Tov H, Kirsner RS, Isseroff RR. Diabetic foot ulcer: an evidence-based treatment update. Am J Clin Dermatol. 2014 Jul;15(3):267-81. doi: 10.1007/s40257-014-0081-9. Review. — View Citation
Cocks K, Torgerson DJ. Sample size calculations for pilot randomized trials: a confidence interval approach. J Clin Epidemiol. 2013 Feb;66(2):197-201. doi: 10.1016/j.jclinepi.2012.09.002. Epub 2012 Nov 27. Review. — View Citation
Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016 Oct 24;355:i5239. doi: 10.1136/bmj.i5239. — View Citation
Game FL, Apelqvist J, Attinger C, Hartemann A, Hinchliffe RJ, Löndahl M, Price PE, Jeffcoate WJ; International Working Group on the Diabetic Foot. Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:154-68. doi: 10.1002/dmrr.2707. Review. — View Citation
Greer N, Foman N, Dorrian J, Fitzgerald P, MacDonald R, Rutks I, Wilt T. Advanced Wound Care Therapies for Non-Healing Diabetic, Venous, and Arterial Ulcers: A Systematic Review [Internet]. Washington (DC): Department of Veterans Affairs; 2012 Nov. Available from http://www.ncbi.nlm.nih.gov/books/NBK132238/ — View Citation
Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat [Internet]. 2005;4(4):287-91. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/pst.185
Karri VV, Kuppusamy G, Talluri SV, Yamjala K, Mannemala SS, Malayandi R. Current and emerging therapies in the management of diabetic foot ulcers. Curr Med Res Opin. 2016;32(3):519-42. doi: 10.1185/03007995.2015.1128888. Epub 2016 Jan 12. Review. — View Citation
NICE Guideline. Diabetic foot problems: prevention and management [Internet]. [cited 2019 Jan 3]. Available from: https://www.nice.org.uk/guidance/ng19
O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. Br J Surg. 2001 Jan;88(1):4-21. Review. — View Citation
Rogers LC, Bevilacqua NJ, Armstrong DG, Andros G. Digital planimetry results in more accurate wound measurements: a comparison to standard ruler measurements. J Diabetes Sci Technol. 2010 Jul 1;4(4):799-802. — View Citation
Schweitzer ME, Daffner RH, Weissman BN, Bennett DL, Blebea JS, Jacobson JA, Morrison WB, Resnik CS, Roberts CC, Rubin DA, Seeger LL, Taljanovic M, Wise JN, Payne WK. ACR Appropriateness Criteria on suspected osteomyelitis in patients with diabetes mellitus. J Am Coll Radiol. 2008 Aug;5(8):881-6. doi: 10.1016/j.jacr.2008.05.002. — View Citation
SIGN. 116 Management of diabetes. A national clinical guideline. 2017; Available from: https://www.sign.ac.uk/assets/sign116.pdf
Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials. 2014 Jul 3;15:264. doi: 10.1186/1745-6215-15-264. — View Citation
Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016 Jun;25(3):1057-73. doi: 10.1177/0962280215588241. Epub 2015 Jun 19. — View Citation
Zimny S, Pfohl M. Healing times and prediction of wound healing in neuropathic diabetic foot ulcers: a prospective study. Exp Clin Endocrinol Diabetes. 2005 Feb;113(2):90-3. — View Citation
* Note: There are 17 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Eligibility rates | Descriptive statistics of number and rate of eligible patients during the period of recruitment | The first 2 months of the trial (untill the last patient has been recruited) | |
Primary | Refusal rates | Descriptive statistics of number and rate of eligible patients that refuse trial participation. | The first 2 months of the trial (untill the last patient has been recruited) | |
Primary | Time from identification to inclusion | Descriptive statistics of average time from eligible patients are identified to they are included in the trial (baseline trial visit) | The first 2 months of the trial (untill the last patient has been recruited) | |
Primary | Qualitative assessment of unexpected factors that must cause exclusion | Qualitatively assessed by the primary investigator | 10 months | |
Primary | Rate of unexpected exclusion | Descriptive statistics of number and rate of patients that are excluded due to reasons not already covered by the trial definition of exclusion criteria. | 10 months | |
Primary | Retention rates | To investigate protocol adherence, the number and rate of participants that adhere to follow-up will be reported. | 10 months | |
Primary | Number of missed trial follow-up visits | To investigate protocol adherence, the number of missed trial visits will be reported for each participant. | 10 months | |
Primary | Drop-out rates | To investigate protocol adherence, the number and rate of participants that choose to drop out during follow-up will be reported. | 10 months | |
Primary | Rate of eligible patients that accept participation | A quantitative investigation of patient acceptability. | At baseline, each follow-up visit and when patients drop out. | |
Primary | Qualitative assessment of patient acceptability | Assessed by interviews with participants. | 10 months | |
Primary | Observed harms and unexpected effects | Observed harms and unexpected effects observed by the investigators and staff will be reported. | 10 months | |
Primary | Patient-reported potential side effects | A qualitatively assessment of harms and unexpected effects by interviewing participants about potential side effects that they experience. | 10 months | |
Primary | Qualitative assessment of logistics issues regarding outpatient clinic visits | The investigators qualitatively assesses logistic circumstances that may be optimized.The assessment includes whether dates of follow-up visits fit the routines at the outpatient clinics. | 10 months | |
Primary | Time to healing of punch biopsy scars | The time to healing will be reported to estimate if and when observer blinding may be possible. | 10 months | |
Primary | Qualitative assessment of the method of wound assessment. | The investigators assess complications related to the method wound bed area and the depth. The aim is to optimize wound assessment for the future definitive trial. | 10 months | |
Primary | Qualitative assessment of the extent of qualitative patient measures | The investigators assess whether the qualitative patient measures are either too extensive or insufficient. Thus, estimating necessary changes to make the qualitative measurements feasible to include in the future definitive trial. | 10 months | |
Primary | Qualitative assessment of the feasibility of culturing 3 biopsies from each round of inforatio technique applications for a future definitive trial. | The investigators assess whether the included centers have the capacity to culture three biopsies two times from each patient. | 10 months | |
Primary | Rates of wound treatments at trial visits that deviate from the trial standard treatment definition | Standard treatments received by each patient at the follow-up visits are recorded and it is assessed whether the standard care received corresponds to the definition of the trial standard treatment. | 10 months | |
Primary | Qualitative assessment of wound care treatments received between trial visits and the deviations from the trial definition of standard treatment. | The investigators assess the heterogeneity of treatment during follow-up by recording the number of hospital visits between the trial follow-up visits and the treatments and assessments received at these hospital visits. | 10 months | |
Primary | Time to healing of the foot ulcers | The investigators will report mean and variance of time to healing | 10 months | |
Primary | Patient-reported experience of trial participation and the inforatio technique | The investigators will interview the patient about their experience of trial participation and of the inforatio technique. | 10 months | |
Primary | Staff acceptability | Assessed qualitatively by interviews with the staff at the outpatient clinics (wound care nurses and podiatrists) | 10 months | |
Primary | Qualitative assessment of the inforatio technique | The method of inforatio technique application will be qualitatively assessed by the applicant. The applicant will report any issues or complications regarding the inforatio technique definition. | 5 months. At baseline application and at the 21-day applications. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04497805 -
Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
|
Phase 2 | |
Withdrawn |
NCT03675269 -
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
|
N/A | |
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06439667 -
VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
|
||
Recruiting |
NCT05608187 -
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Not yet recruiting |
NCT06437028 -
Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers.
|
N/A | |
Withdrawn |
NCT05024656 -
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT02202668 -
Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01951768 -
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
|
Phase 4 | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT01657474 -
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
|
N/A | |
Active, not recruiting |
NCT00389636 -
TheraGauzeā¢ Alone and Regranex®Gel 0.01% Plus TheraGauzeā¢ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01181440 -
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT05888259 -
Plantar Pressure Distribution in Diabetic Foot Ulcer
|
N/A | |
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Not yet recruiting |
NCT05877378 -
Efficacy of PICO Single-use System in Chronic Ulcers
|
N/A | |
Recruiting |
NCT06037369 -
The Short Message-based Customized Standardized
|
N/A | |
Completed |
NCT03312595 -
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
|
N/A | |
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A |